Speaker(s): 

Faustin Mambulu, MD- Internal Medicine Resident PGY-3, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Connor Dougherty, DO, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Recognize HFpEF as a major contributor to heart failure hospitalizations and readmissions in the inpatient setting.
• Interpret high quality clinical trial evidence supporting SGLT2 inhibitor therapy in HFpEF (Level of IIA).
• Apply guideline recommended  SGLT2 inhibitor therapy (Class IIa) to appropriate hospitalized HFpEF patients prior to discharge.
• Manage inpatient safety considerations and contraindications associated with SGLT2 inhibitor initiation.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Connor Dougherty, DO, Karlyn Paglia, MD, Juan R. Escobar, MD, Melad Kamel, MD, Shashank Kotakonda, MD, Jayalakshmi Nair, MD, Jignesh Patel, MD, Jameson Woodard, MD, Hasan Zerti, MD, Robert Yanoshak, DO, and Habib Hamoud, MD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.